RLFFD - RLFFD STOCK NEWS

Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with the potential for an additional $46.5 million in milestone and royalty payments. The transition to a revenue-based royalty stream model is expected to deliver earlier returns and enhanced predictability to Relief Therapeutics.

Relief Therapeutics announces the results of its Annual General Meeting (AGM) of shareholders. Certain proposed items by the board of directors did not receive majority approval, possibly due to differences in opinion on the future development of the company. The rejected proposals will be reviewed and analyzed. The AGM approved the annual report and financial statements for 2022, but denied discharge to the board of directors and executive committee for their activities in 2022. The capital band and conditional share capital remain unchanged. Most proposed amendments to the Articles of Association were approved, except for compensation-related amendments. Compensation proposals for board members and the executive committee were rejected. Existing board members were re-elected, including Dr. Raghuram Selvaraju as chairman. The nomination and compensation committee, independent voting rights representative, and auditors were also re-elected.